As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...
WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated ...
Everyday Health on MSN
Experimental Obesity Drug Could Soon Compete With Wegovy and Zepbound
Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...
Woman's World on MSN
Dr Blitz: TrumpRx Deal for Wegovy and Zepbound ‘Just What the Doctor Ordered'
After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...
Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School ...
Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes.
Hims & Hers Health, Inc. could see more upside in partnerships and international expansion. Click here to read an analysis of ...
The White Houes may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss ...
Novo Nordisk is under pressure from cheap copycats, a Trump pricing deal, and Lilly's fast-growing Zepbound juggernaut.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback